CardioDx Raises $40M


Palo Alto, CA-based CardioDx, which developes genomic tests assessing patients’ risk of developing cardiovascular disease, has raised $40 million in a round of equity-based financing, according to a regulatory filing. New investor Longitude Capital led the Series E round, according to a report in Dow Jones VentureWire. CardioDx’s existing investors include Kleiner Perkins Caufield & Byers, TPG Biotech, MDV, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, and GE Capital.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can subscribe to his Google Group or e-mail him at Follow @

By posting a comment, you agree to our terms and conditions.